Blueprint Medicines is a pioneering biopharmaceutical company based in Cambridge, MA, dedicated to transforming science into more time for life. With a relentless commitment to accelerating the development of new therapies, they strive to expedite clinical trials and bring approved medicines to patients worldwide, focusing on genomically defined diseases. Their diverse team of passionate individuals thrives on innovation, making bold decisions, and pioneering novel solutions to improve the lives of people with advanced gastrointestinal stromal tumors, systemic mastocytosis, and other diseases.
At Blueprint Medicines, they help patients stay one step ahead with precision therapies that adapt to disease evolution, solving for treatment resistance and intractable sites of progression. Their platform is driven by a deep understanding of selective kinase medicines and a discovery engine that sparks innovation. With a commitment to patients, they aim to dramatically improve lives by providing innovative treatments and prolonging benefits through pioneering combinations. Through their clinical programs and pipeline, Blueprint Medicines is dedicated to making a meaningful impact on the lives of patients worldwide.
Generated from the website